ライフサイエンスコーパス: scintigraphy

1 intestinal radiography, and gastrointestinal scintigraphy.

2 catheter and small intestinal transit using scintigraphy.

3 elate to findings based on Abeta and tau PET scintigraphy.

4 and whole-body MRI were performed after bone scintigraphy.

5 %, 81%, and 86%, respectively, for leukocyte scintigraphy.

6 abeled mashed potato meal was measured using scintigraphy.

7 tion in rabbits were investigated with gamma-scintigraphy.

8 uptake on (99m)Tc-PAMA-cobalamin whole-body scintigraphy.

9 s purpose are ultrasonography and MIBI-Tc99m scintigraphy.

10 ter perfusion defect on myocardial perfusion scintigraphy.

11 amyloid load was measured by serum amyloid P scintigraphy.

12 cal planning and is superior to conventional scintigraphy.

13 afe, cost-effective alternative to sestamibi scintigraphy.

14 tion exposure with similar cost to sestamibi scintigraphy.

15 al of the infused nutrient was determined by scintigraphy.

16 e basis of method ultrasonography and planar scintigraphy.

17 tive expression of tumor burden seen on bone scintigraphy.

18 ressing tumor xenografts and imaged by gamma-scintigraphy.

19 wed good agreement with myocardial perfusion scintigraphy.

20 ith Paget disease were true positive only at scintigraphy.

21 using (99m)Tc-mercaptoacetyltriglycine renal scintigraphy.

22 detected by (99m)Tc-pertechnetate or (123)I scintigraphy.

23 uclide studies consisting of PET-CT and MIBG scintigraphy.

24 d further characterized with PET-CT and MIBG scintigraphy.

25 cociliary clearance was measured using gamma scintigraphy.

26 (US) and technetium 99m ((99m)Tc) sestamibi scintigraphy.

27 to facilitate quantitative analyses by gamma-scintigraphy.

28 hono-1,2-propanodicarboxylic-acid (DPD) bone scintigraphy.

29 practice guidelines and the current role of scintigraphy.

30 nts each) were assessed by sequential planar scintigraphy (1, 5, and 24 h after injection).

31 Gastric emptying (scintigraphy, 100 mL of Ensure (Abbott Australia, Kurnel

32 e injected intravenously, followed by (123)I scintigraphy, (124)I PET imaging, and (131)I therapy.

33 Compared with conventional scintigraphy, (64)Cu-DOTATATE PET identified additional

34 ith a combination of whole-body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs. 83.0%

35 < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs. 65.9

36 contrast enhanced MR urography for RS renal scintigraphy acceptable.

37 Bone scintigraphy accurately diagnoses osteomyelitis in bones

38 The combined use of mammography and scintigraphy achieved 100% sensitivity.

39 g the performance and interpretation of lung scintigraphy across 3 different countries.

40 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (18)F-FDG PET, using tumor histology as

41 ts and might be complementary to (123)I-MIBG scintigraphy and (18)F-FDG PET.

42 techniques ((99m)Tc-galactosyl serum albumin scintigraphy and (99m)Tc-mebrofenin hepatobiliary scinti

43 Results of bone scintigraphy and biochemical investigations were analyze

44 with symptomatic PE underwent perfusion lung scintigraphy and blood gas analysis within 48 h from cli

45 using specific search terms, including both scintigraphy and C13-octanoic acid breath test.

46 aging methods such as echocardiography, bone scintigraphy and cardiovascular MRI.

47 Patients underwent myocardial scintigraphy and cells were injected in the artery suppl

48 It is superior to (131)I-MIBG scintigraphy and conventional imaging (CT/MR imaging) fo

49 131)I-metaiodobenzylgunanidine ((131)I-MIBG) scintigraphy and conventional imaging (CT/MR imaging) of

50 Skeletal scintigraphy and cross-sectional imaging confirmed wides

51 Although nuclear scintigraphy and CTA had similar sensitivity and specifi

52 tion were confirmed in mice by (111)In gamma scintigraphy and fluorescence microscopy demonstrating t

53 The difference in sensitivity between scintigraphy and mammography was not statistically signi

54 patic amyloid load, as shown by means of SAP scintigraphy and measurement of extracellular volume by

55 KCD26) HEK cells and characterized by planar scintigraphy and organ distribution studies in tumor-bea

56 dels including the visual assessment of bone scintigraphy and other relevant covariates.

57 Peptide receptor scintigraphy and peptide receptor radionuclide therapy a

58 such as JR11 might enhance peptide receptor scintigraphy and peptide receptor radionuclide therapy o

59 xamples of theranostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy o

60 Peptide receptor scintigraphy and peptide receptor radionuclide therapy u

61 The annual use of bone scintigraphy and radiotracer therapies was unchanged.

62 Clinicians currently use planar scintigraphy and single-photon emission computed tomogra

63 e (99m)Tc-FAPI-34 was applied for diagnostic scintigraphy and SPECT of patients with metastasized ova

64 CCK2R tumor xenografts and examined by gamma scintigraphy and SPECT/CT.

65 to diagnose dysfunction (dynamic gallbladder scintigraphy and sphincter manometry) is controversial.

66 Most importantly, sstr scintigraphy and sstr PET/CT can distinguish patients wh

67 2 or 3 myocardial radiotracer uptake on bone scintigraphy and the absence of a monoclonal protein in

68 sm of these coated virus particles by (123)I scintigraphy and to evaluate their therapeutic potential

69 eted images from CT, whole-body MRI, or bone scintigraphy and were blinded to results with the other

70 the results with those for (99m)Tc-MDP bone scintigraphy and whole-body MRI.

71 ors and sympathetic integrity (from the MIBG scintigraphy) and the 30-to-15 ratio (a CART), remained

72 vailable bone scintigraphy, white blood cell scintigraphy, and (18)F-FDG PET/CT results.

73 ely 93% and 100% for (123) I-MIBG myocardial scintigraphy, and 90% and 76% for (123) I-FP-CIT SPECT.

74 Computed tomography, bone scintigraphy, and lumbar spine x-rays were performed at

75 OTATATE PET/CT, (111)In-pentetreotide planar scintigraphy, and SPECT/CT within 1 wk.

76 rity as measured by both radiograph and bone scintigraphy, and synovial fluid IL-1beta was associated

77 ic diagnosis was obtained in all cases after scintigraphy, and the scintigraphic findings were correl

78 ng, including radiographs, CT, MRI, and bone scintigraphy, are recognized as being insensitive and no

79 ator and support further exploration of bone scintigraphy as an imaging biomarker in CRMPC.

80 elines recommend ventilation-perfusion (V/Q) scintigraphy as the imaging modality of choice to exclud

81 radiation-associated procedure; use of lung scintigraphy as the preferred test in the setting of a n

82 score based on (111)In-pentetreotide planar scintigraphy as was performed in the NETTER-1 trial.

83 various imaging examinations, including bone scintigraphy as well as CT and MRI of the lumbosacral sp

84 evascularization as detected with myocardial scintigraphy at 12 months.

85 Moreover, scintigraphy better assessed disease extent than did mam

86 d with bone marrow histology and bone marrow scintigraphy (BMS), the gold standard techniques in this

87 assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who hav

88 of cartilage remodeling by (99m)Tc-NTP 15-5 scintigraphy, bone damages by (99m)Tc-hydroxymethylene d

89 s of overuse defined as combined use of bone scintigraphy (BS) and PET, which current guidelines reco

90 BC) by (18)F-FDG PET instead of (99m)Tc bone scintigraphy (BS) supports clinically relevant changes i

91 s suggestive of cardiac amyloidosis, cardiac scintigraphy can confirm the diagnosis of ATTR-CM only w

92 igraphy and (99m)Tc-mebrofenin hepatobiliary scintigraphy) can measure both total and future remnant

93 valuated using hematologic parameters, renal scintigraphy, clinical data, and the prostate-specific a

94 patient has been performed with radiography, scintigraphy, computed tomography, magnetic resonance im

95 catheterization, ventilation-perfusion lung scintigraphy, computerized tomography, and/or pulmonary

96 any nodal and lung metastases from dogs, and scintigraphy confirmed folate uptake in both primary and

97 se in 1 of 7 patients (14%), while sestamibi scintigraphy correctly predicted multiglandular disease

98 pre-angiography test, compared with nuclear scintigraphy, CTA reduced overall the number of imaging

99 rk to PET/CT activity concentrations, planar scintigraphy data, and tumor volumes before and after (6

100 eased from 3.8% to 56.6%, and use of nuclear scintigraphy decreased from 83.3% to 50.6% following pro

101 Nuclear scintigraphy delineated bolus-induced deglutitive reflux

102 Dynamic parathyroid CT and sestamibi scintigraphy delivered mean radiation doses of 5.56 and

103 In our series, BSGC scintigraphy demonstrated a slightly higher sensitivity

104 thyroid CT and a mean of $1112 for sestamibi scintigraphy, depending on the type and amount of radiot

105 combination of CT/MR imaging and (131)I-MIBG scintigraphy detected only 53 of 78 (67.9%) lesions and

106 a of the gall bladder is rare and hence bone scintigraphy does not form a part of the routine work-up

107 Bone scintigraphy enables the diagnosis of cardiac ATTR amylo

108 s well standardized as gastric emptying (GE) scintigraphy, esophageal transit scintigraphy, if perfor

109 represents a powerful tracer for diagnostic scintigraphy, especially when PET imaging is not availab

110 thyroid nodules is challenging since thyroid scintigraphy fails to distinguish between benign and mal

111 Planar scintigraphy followed by SPECT imaging was performed aft

112 and no tumor uptake were observed on planar scintigraphy for a HT-1080-FAP-xenotransplanted mouse.

113 t either dynamic parathyroid CT or sestamibi scintigraphy for any etiology of hyperparathyroidism fro

114 cal failure had negative NaF PET/CT and bone scintigraphy for bone metastases.

115 r 55%+/-11%), underwent myocardial perfusion scintigraphy for documentation of reversible perfusion d

116 s superior to whole-body MRI and (99m)Tc-MDP scintigraphy for evaluation of skeletal disease extent.

117 Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment

118 contrast enhanced MR urography and RS renal scintigraphy for measurement of SRF split renal function

119 e, replace technetium-99m diphosphonate bone scintigraphy for osteomedullary metastasis assessment.

120 ing as a first-line alternative to sestamibi scintigraphy for preoperative localization of parathyroi

121 lization should undergo both angiography and scintigraphy for the assessment of hepaticoenteric arter

122 te scintigraphy (LS), and Gallium-67 citrate scintigraphy for the diagnosis of CIED infection.

123 e performance of (18)F-FDG PET and leukocyte scintigraphy for the diagnosis of PVE in 39 patients.

124 l distribution (IMD) during gastric emptying scintigraphy (GES) allows for a simple measure of FA.

125 lasia, peptic ulcer, normal gastric emptying scintigraphy (GES) and prepyloric tumors were excluded.

126 ur colloid ((99m)Tc-SC) for gastric emptying scintigraphy (GES).

127 ging group (gadoterate meglumine), and renal scintigraphy group ((99m)Tc).

128 In the MR imaging and renal scintigraphy groups, there were significant changes in s

129 Although ventilation/perfusion scintigraphy has been supplanted by computed tomographic

130 Whole-body scintigraphy has shown rapid mIBG elimination through th

131 GE scintigraphy has undergone much-needed standardization.

132 erein findings on technetium-labeled cardiac scintigraphy have been misinterpreted, reviews causes of

133 ron emission tomography and white blood cell scintigraphy have been shown to reduce the rate of misdi

134 Background CT and bone scintigraphy have limitations in evaluating systemic ant

135 ) I-FP-CIT SPECT and (123) I-MIBG myocardial scintigraphy have similar sensitivity for detecting DLB,

136 ate the complementary value of hepatobiliary scintigraphy (HBS) before and after radioembolization in

137 Technetium-labeled cardiac scintigraphy (i.e., Tc-PYP scan) has been repurposed for

138 ptying (GE) scintigraphy, esophageal transit scintigraphy, if performed in a comprehensive manner inc

139 gation test 1 week later and interpreted the scintigraphy images at the end of the study.

140 Planar scintigraphy imaging followed by SPECT/CT imaging was ob

141 (Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and

142 126425; Meta-Iodobenzylguanidine [123I-mIBG] Scintigraphy Imaging in Patients With Heart Failure and

143 ll with historical data derived using (131)I scintigraphy imaging, whereas the response rate for LMs

144 ubsequent SACT based on standard CT and bone scintigraphy imaging.

145 ility of (99m)Tc-pyrophosphate ((99m)Tc-PYP) scintigraphy in AL versus ATTR.

146 essive disease (PD) earlier than CT and bone scintigraphy in bone-only MBC.

147 cation of SPECT/CT technology to radioiodine scintigraphy in both diagnostic and post-therapy setting

148 lness of breast-specific gamma-camera (BSGC) scintigraphy in DCIS identification, describing the scin

149 nd dog bladder tissues together with nuclear scintigraphy in dogs to monitor iUC folate uptake.

150 of (18)F-FDG PET and radiolabeled leukocyte scintigraphy in IE patients has already been reported.

151 with Tc-99m-mercapto-acetyltriglycin (MAG3) scintigraphy in living kidney donation.

152 tigated the reliability of (99m)Tc-sestamibi scintigraphy in monitoring changes in bone marrow involv

153 of a combination of whole-body MRI and bone scintigraphy in patients with breast and prostate cancer

154 used 3-d protocol for somatostatin receptor scintigraphy in patients with gastroenteropancreatic neu

155 rgery, dynamic CT is comparable to sestamibi scintigraphy in patients with hyperparathyroidism.

156 m)Tc-mercaptoacetyltriglycine ((99m)Tc-MAG3) scintigraphy in patients with renal insufficiency.

157 dy to ascertain the diagnostic value of bone scintigraphy in this disease.

158 We assessed the value of (99m)Tc-HMPAO-WBC scintigraphy including SPECT/CT acquisitions in a series

159 Conclusion: Integration of thyroid scintigraphy into the TIRADS model is essential to preve

160 rointestinal tract, gastrointestinal transit scintigraphy is a uniquely suited noninvasive, quantitat

161 Splenic scintigraphy is an economical, accessible and accurate t

162 inated metaiodobenzylguanidine ((123)I-mIBG) scintigraphy is an established imaging method in neurobl

163 Gastric emptying scintigraphy is considered to be the gold standard for d

164 Therefore, thyroid scintigraphy is essential for the detection of HTNs.

165 scanning took less than 5 minutes, sestamibi scintigraphy lasted a mean time of 306 minutes.

166 reasing organ amyloid burden assessed at SAP scintigraphy (liver, rs = 0.54; spleen, rs = 0.57).

167 mates from 256-slice CTPA and lung perfusion scintigraphy (LPS) for comparison.

168 y and computed tomography, labeled leukocyte scintigraphy (LS), and Gallium-67 citrate scintigraphy f

169 Conclusion: Perfusion scintigraphy may be useful to follow patients with PE.

170 No studies for (67)Ga citrate scintigraphy met the inclusion criteria.

171 ve echocardiogram and a myocardial perfusion scintigraphy (MPS) at inclusion.

172 severity of ischemia on myocardial perfusion scintigraphy (MPS) is commonly used to risk-stratify pat

173 recurring; thus, stress myocardial perfusion scintigraphy (MPS) is widely used to identify ischemia i

174 Compared with stress myocardial perfusion scintigraphy (MPS), CCTA was associated with an increase

175 Whether abnormal myocardial perfusion scintigraphy (MPS), dobutamine stress echocardiography (

176 opriateness ratings for myocardial perfusion scintigraphy (MPS), stress echocardiography (STE), or co

177 trated a higher sensitivity than (123)I-MIBG scintigraphy (n = 18; P = 0.0455) or (18)F-FDG PET (n =

178 symptomatic, underwent protocolized nuclear scintigraphy (n=83), 24-hour esophageal pH monitoring, a

179 If neither conventional bone scintigraphy nor NaF PET were available, referring physi

180 c MRI with gadolinium and (123)I-labeled SAP scintigraphy not only assist in evaluation of patients w

181 n the results of (18)F-FDG PET and leukocyte scintigraphy occurred in 12 patients (31%).

182 myocardial ischemia on myocardial perfusion scintigraphy of all parameters was compared using receiv

183 In vivo (123)I scintigraphy of nude mice revealed significantly reduced

184 Leukocyte scintigraphy offers a higher specificity, however, than

185 ergoing restaging with somatostatin receptor scintigraphy on a modern SPECT/CT device were enrolled i

186 in 54 of 62 patients (87%), while sestamibi scintigraphy only correctly lateralized 90 of 122 adenom

187 udies with optimal or moderate test methods (scintigraphy or breath test, solid meal, >2 hours durati

188 n in ischemic burden on myocardial perfusion scintigraphy or in the safety endpoints of major bleedin

189 ional CT, appropriately supplemented by bone scintigraphy or other modalities), was defined prospecti

190 mptying, based on (99m)technetium-mebrofenin scintigraphy or post-prandial variations in gallbladder

191 h, including testing for monoclonal protein, scintigraphy, or biopsy and, if ATTR associated with car

192 lene-diphosphonate ((99m)Tc-HDP) planar bone scintigraphy (pBS), (99m)Tc-HDP SPECT/CT, (18)F-NaF PET/

193 Gastrointestinal bleeding scintigraphy performed with (99m)Tc-labeled autologous e

194 hono-1,2-propanodicarboxylic acid (DPD) bone scintigraphy (Perugini grade 0: negative; grades 1 to 3:

195 Standard scintigraphy plays a crucial role, and data from positro

196 In patients with RA, scintigraphy plays a key role in the differential diagno

197 Parathyroid scintigraphy plays a major role in defining the surgical

198 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy plays an important role in the diagnostic e

199 After baseline scintigraphy, PMPA was injected in doses of 0.2-50 mg/kg

200 BSGC scintigraphy proved to be a highly sensitive diagnostic

201 Radionuclide renal scintigraphy provides important functional data to assis

202 trinary interpretation strategy for V/Q lung scintigraphy provides outcomes similar to traditional pr

203 invasive imaging of NIS expression by (123)I scintigraphy-provides detailed characterization of in vi

204 an include a ultrasonography (US) and planar scintigraphy (PS) whose characterized by noninvasive.

205 (SC) or 2-dimensional planar lung perfusion scintigraphy (PS).

206 ) or a two-dimensional planar lung perfusion scintigraphy (PS).

207 gamma-Scintigraphy quantified the uptake of studied radiolabel

208 before and immediately after diuretic renal scintigraphy (reference standard for presence of urinary

209 Bone scintigraphy remains the most commonly used imaging tool

210 ((123)I-MIBG) was examined by PET and planar scintigraphy, respectively.

211 been excluded, 6 had true-negative leukocyte scintigraphy results but false-positive (18)F-FDG PET re

212 and heart disease on (123) I-MIBG myocardial scintigraphy results might have been overestimated.

213 sk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.

214 requency Questionnaire, and gastric emptying scintigraphy results were analyzed.

215 (99m)Tc-HMPAO-WBC scintigraphy results were correlated with transthoracic

216 FDG PET results but false-negative leukocyte scintigraphy results.

217 (18)F-FDG PET results and negative leukocyte scintigraphy results.

218 Scintigraphy revealed abnormal hot spots in subcutaneous

219 peutic (131)I imaging comprised a whole-body scintigraphy scan and a SPECT/CT scan of the neck to dis

220 All perfusion lung scintigraphy scans were examined by 2 expert nuclear med

221 mission computed tomography and quantitative scintigraphy (see scheme).

222 Presently, (99m)Tc-mebrofenin hepatobiliary scintigraphy seems to be the most valuable quantitative

223 Thus, BSGC scintigraphy should represent a useful adjunctive tool i

224 (131)I-MIBG scintigraphy showed only 30 of the 78 lesions and was in

225 so underwent serum amyloid P (SAP) component scintigraphy so that specific organ involvement by amylo

226 )In-DTPA(0)]octreotide somatostatin receptor scintigraphy (SRS) before treatment, and who had soft-ti

227 ing studies in the pre-somatostatin receptor scintigraphy (SRS) era, and 23 patients in the post-SRS

228 ative conventional and somatostatin receptor scintigraphy (SRS) results were studied.

229 -up comprised CT scan, (111)In-pentetreotide scintigraphy (SRS), and (18)F-FDG PET.

230 MR, together with the somatostatin receptor scintigraphy (SRS), in each clinically suspicious case.

231 de (HYNIC)-octreotide (somatostatin receptor scintigraphy [SSRS]) SPECT/CT, (68)Ga-DOTATATE PET/CT, a

232 (EXINI Bone(BSI)) was obtained for baseline scintigraphy studies and follow-up scans after 3 cycles

233 Bone scintigraphy studies were reviewed and graded according

234 3D-printed anatomic replicas using the gamma scintigraphy technique.

235 t, include magnetic resonance imaging (MRI), scintigraphy techniques (SPECT) and PET.

236 By nuclear scintigraphy, the biodistribution of Pam-Doxo-NPs demons

237 apy have led to rapid adoption of diagnostic scintigraphy, there is heterogeneity in adherence to con

238 but correctly negative at (99m)Tc-HMPAO-WBC scintigraphy: these patients had marantic vegetations.

239 When patients returned for whole-body scintigraphy, thyroid, half-life, and whole-body half-li

240 med using technetium-pertechnetate and gamma-scintigraphy to assess determining factors for radioupta

241 ar MRI with tissue characterization and bone scintigraphy to diagnose cardiac amyloidosis has revolut

242 roaggregated albumin ((99m)Tc-MAA) perfusion scintigraphy to estimate the liver-to-lung shunt and exc

243 there is a need to expand the analysis of GE scintigraphy to include the separate roles of the fundus

244 rvation, 123I-metaiodobenzylguanidine (MIBG) scintigraphy to measure cardiac sympathetic innervation,

245 demonstrate the ability of (99m)Tc-HMPAO-WBC scintigraphy to reduce the rate of misdiagnosed cases of

246 been recognized that technetium-labeled bone scintigraphy tracers can localize to myocardial amyloid

247 ance imaging and cardiac repurposing of bone scintigraphy tracers.

248 ice catheter cerebral angiography, perfusion scintigraphy, transcranial Doppler sonography, CT angiog

249 of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy.

250 ivocal for uptake on (111)In-DTPA-octreotide scintigraphy underwent (68)Ga-DOTATATE PET.

251 Perfusion scintigraphy using (99m)Tc-labeled albumin aggregates is

252 efore surgery, all patients underwent breast scintigraphy using a high-resolution semiconductor-based

253 ssess the level of agreement between PET and scintigraphy using diagnostic amounts of (124)I and ther

254 thies, myocardial radiotracer uptake on bone scintigraphy was >99% sensitive and 86% specific for car

255 interval between (18)F-FDG PET and leukocyte scintigraphy was 7 +/- 7 d.

256 and October 2015 and for whom baseline bone scintigraphy was available.

257 crepancy between (18)F-FDG PET and leukocyte scintigraphy was classified as having possible endocardi

258 he value of (18)F-FDG PET/CT and (123)I-BZA2 scintigraphy was compared for melanoma staging.

259 Cardiac (123)I-metaiodobenzylguanidine scintigraphy was conducted in a subgroup of 29 patients

260 Progressive disease at bone scintigraphy was evident in only half of participants wi

261 oth 4 and 24 h after PRLT, whole-body planar scintigraphy was performed.

262 Scintigraphy was positive in 31 of 33 patients (sensitiv

263 Gastric scintigraphy was preoperatively performed in all patient

264 Clinical gamma scintigraphy was proved feasible to explore spatial- and

265 PD at bone scintigraphy was reported in 50% of participants (13 of

266 c contrast enhanced MR urography to RS renal scintigraphy was shown, with a standard deviation of app

267 Scintigraphy was true-positive in 46 of 51 and false-neg

268 (99m)Tc-MAA planar scintigraphy was used for liver-to-lung shunt estimation

269 In case of PD, bone scintigraphy was used to assess for bone disease progres

270 hy was used compared with that when RS renal scintigraphy was used.

271 ing with a Tc(99m)-labelled meal followed by scintigraphy was utilized.

272 mucosal medication contact time, measured by scintigraphy, was higher for the OVB group than the NEB

273 (99m)Tc]-diethylenetriamine pentaacetic acid scintigraphy, was reduced by TM(inh)-23 by ~60% at 20 mi

274 However, a tumor-negative (131)I whole-body scintigraphy (WBS) prevails in 38%-50% of patients.

275 ariability measurements and gastric emptying scintigraphies were performed in all subjects to obtain

276 The results of (18)F-FDG PET and leukocyte scintigraphy were analyzed separately and retrospectivel

277 our pediatric radiology department for bone scintigraphy were evaluated.

278 SPECT/CT and planar scintigraphy were performed at the same posttreatment in

279 (18)F-FDG PET and leukocyte scintigraphy were performed on 39 consecutive patients a

280 e cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study.

281 nclusive results at US and (99m)Tc sestamibi scintigraphy were prospectively enrolled.

282 cancer with negative findings on CT and bone scintigraphy were referred for (18)F-DCFPyL (2-(3-(1-car

283 therapeutic radiopharmaceutical use and bone scintigraphy were unchanged.

284 t CTEPH should include ventilation-perfusion scintigraphy, which has high sensitivity and a negative

285 these tests, she was referred for whole-body scintigraphy, which revealed an unexpected finding that

286 sults were also compared with available bone scintigraphy, white blood cell scintigraphy, and (18)F-F

287 high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy.

288 Whole-body scintigraphy with (111)In-pentetreotide has revolutioniz

289 Planar scintigraphy with (123)I/(99m)Tc-sestamibi performs well

290 udy was to compare the performance of planar scintigraphy with (123)I/(99m)Tc-sestamibi, (99m)Tc-sest

291 ected utilizing dual perfusion and metabolic scintigraphy with (201)Tl/(123)I-BMIPP, which was reliev

292 erwent angiographic assessment and perfusion scintigraphy with (99m)Tc-MAA before lobar (90)Y radioem

293 Scintigraphy with (99m)Tc-nanocolloid was able to confir

294 Scintigraphy with (99m)Tc-sestamibi allows differentiati

295 Thyroid scintigraphy with either radioiodine or (99m)Tc-pertechn

296 on monoxide (DLCO), Tc99m-MAA lung perfusion scintigraphy with PS and SPECT/CT quantification.

297 ) I-FP-CIT SPECT and (123) I-MIBG myocardial scintigraphy within a few weeks of clinical diagnosis.

298 a single (111)In-girentuximab injection and scintigraphy without any treatment.

299 NaF PET were unavailable, conventional bone scintigraphy would have been ordered in 85% of patients.

300 nonbiopsy diagnosis of ATTR-CM using cardiac scintigraphy, yet emphasize its use in the appropriate c